Skip to content

Study on metabonomics of Chinese herbal medicine in the treatment of type 2 diabetes mellitus complicated with community-acquired pneumonia

Study on metabonomic regularity of type 2 diabetes mellitus complicated with community-acquired pneumonia and its intervention by Traditional Chinese medicine.

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000035204
Enrollment
Unknown
Registered
2020-08-03
Start date
2020-08-02
Completion date
Unknown
Last updated
2020-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus complicated with community-acquired pneumonia

Interventions

Sponsors

Hospital of Chengdu University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria for T2DM-CAP group 1. Participants have a history of type 2 diabetes and are hospitalized with confirmed CAP. 2. Participants meet the criteria for pulmonary-splenic asthenia and accumulation of phlegm-dampness syndrome in TCM. 3. Participants Participants aged 18–70 years, no gender limitations. 4. Participants can complete this study and all tests. 5. Participants provide informed written consent and volunteer to participate in the trial. Inclusion criteria for T2DM group: 1. Patients who meet the diagnostic criteria of diabetes, that is, the fasting blood glucose level is greater than or equal to 7.0 mmol / L, and the postprandial blood glucose is greater than or equal to 11.1 mmol / L. 2. Participants Participants aged 18–70 years, no gender limitations. 3. Participants provide informed written consent and volunteer to participate in the trial. Inclusion criteria for CAP group 1. Patients who meet the diagnostic criteria of CAP. 2. Participants Participants aged 18–70 years, no gender limitations. 3. Participants provide informed written consent and volunteer to participate in the trial.

Exclusion criteria

Exclusion criteria: Exclusion criteria for T2DM-CAP group 1. Patients with other coexistent pulmonary diseases (e.g., bronchiectasis,pulmonary edema, chronic obstructive pulmonary disease, tuberculosis, or interstitial lung disease). 2. Patients with severe comorbidities, such as malignant tumors, infectious diseases, coronary heart disease, mental abnormality or patients whose laboratory data indicating severe systemic disease (such as liver and kidney dysfunction). 3. Patients complicated with other infectious diseases; 4. Women who are breastfeeding, or pregnant. 5. Allergies for experimental drugs or Chinese herbal medicine. 6. Patients have participated in other clinical trials in the one month preceding the trial. Exclusion criteria for T2DM group 1. Combined with CAP, tuberculosis and other infectious diseases; 2. Patients with severe comorbidities, such as malignant tumors, infectious diseases, coronary heart disease, mental abnormality or patients whose laboratory data indicating severe systemic disease (such as liver and kidney dysfunction). 3. Women who are breastfeeding, or pregnant. 4. Patients with acute metabolic disorders such as diabetic ketoacidosis in the past month. Exclusion criteria for CAP group 1. Ccomplicated with other lung diseases (COPD, pulmonary tuberculosis, bronchial asthma, etc.). 2. Complicated with diabetes. 3. patients with severe complications, such as malignant tumors, infectious diseases, coronary heart disease, mental disorders or laboratory data show severe systemic diseases (such as hepatorenal dysfunction). 4. Women who are breastfeeding, or pregnant. 5. Complicated with other infectious diseases.

Design outcomes

Primary

MeasureTime frame
Total clinical effective rate of pneumonia;

Secondary

MeasureTime frame
TCM symptom score scale;Time required for pneumonia control;Time required for blood glucose to reach standard;Frequency of hypoglycemia;Inflammatory biomarkers;chest CT;Differences in blood metabolomics;blood glucose;HbA1c;

Countries

China

Contacts

Public ContactRensong Yue

Hospital of Chengdu University of Traditional Chinese Medicine

738118482@qq.com+86 13880336152

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 17, 2026